Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials

Linda Spiegelberg, Ruud Houben, Raymon Niemans, Dirk de Ruysscher, Ala Yaromina, Jan Theys, Christopher P. Guise, Jeffrey B. Smaill, Adam V. Patterson, Philippe Lambin, Ludwig J. Dubois*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)62-69
Number of pages8
JournalClinical and Translational Radiation Oncology
Volume15
DOIs
Publication statusPublished - Feb 2019

Keywords

  • Hypoxia-activated prodrugs
  • Phase III clinical trial
  • Biomarker
  • Hypoxia
  • C P450 REDUCTASE
  • POSITRON-EMISSION-TOMOGRAPHY
  • SQUAMOUS-CELL CARCINOMAS
  • OXYGEN-ENHANCED MRI
  • TUMOR HYPOXIA
  • ANTITUMOR-ACTIVITY
  • NECK-CANCER
  • LUNG-CANCER
  • EXTRAVASCULAR TRANSPORT
  • EVOFOSFAMIDE TH-302

Cite this